Article By:
MoneyShow.com
Monday, May 9, 2022 9:54 AM EDT
The firm’s big money-making drug, Revlimid (acquired when it bought Celgene a few years back), which treats a cancer of plasma cells called multiple myeloma, is facing increasing generic competition.
In this article: BMY
Macy’s Q1 Was Bad, But The Company Has The Cash To Survive The Current Pandemic
Glad you liked it Sheryl! Right now I think a range of REITs and healthcare stocks are attractive from a risk-reward standpoint, including $ABBV, $BMY, $O, $SLG, $SPG, etc.
Bristol-Meyers (BMY) Head And Shoulders Pattern
I fear bad news is acoming for $BMY.
Bristol-Myers To Buy Celgene; A $74 Billion Deal
Nice info, thanks for sharing with us. Bullish on $BMY
OncoSec Raising Its Profile In Fight Against Cancer
Very impressed with the #OncosSec trial results. $ONCS $MRK $BMY